Nature Reviews Drug Discovery, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 28, 2025
Language: Английский
Citations
4Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1778 - 1778
Published: Feb. 19, 2025
In recent years, “metabolic dysfunction-associated steatotic liver disease” (MASLD) has been proposed to better connect disease metabolic dysfunction, which is the most common chronic worldwide. MASLD affects more than 30% of individuals globally, and it diagnosed by combination hepatic steatosis obesity, type 2 diabetes, or two risk factors. begins with buildup extra fat, often greater 5%, within liver, causing hepatocytes become stressed. This can proceed a severe form, steatohepatitis (MASH), in 20–30% people, where inflammation causes tissue fibrosis, limits blood flow over time. As fibrosis worsens, MASH may lead cirrhosis, failure, even cancer. While pathophysiology not fully known, current “multiple-hits” concept proposes that dietary lifestyle factors, genetic epigenetic factors contribute elevated oxidative stress inflammation, fibrosis. review article provides an overview pathogenesis evaluates existing therapies as well pharmacological drugs are currently being studied clinical trials for MASH.
Language: Английский
Citations
2Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?
Expert Opinion on Pharmacotherapy, Journal Year: 2024, Volume and Issue: 25(9), P. 1249 - 1263
Published: June 12, 2024
Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined by hepatic steatosis and cardiometabolic risk factors like obesity, type 2 diabetes, dyslipidemia. Persistent metabolic injury may promote inflammatory processes resulting in steatohepatitis (MASH) fibrosis. Mechanistic insights helped to identify potential drug targets, thereby supporting the development of novel compounds modulating drivers.
Language: Английский
Citations
8Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Nature Reviews Drug Discovery, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 28, 2024
Language: Английский
Citations
4Deficiency of hepatokine orosomucoid1 aggravates NAFLD progression in mice
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2025, Volume and Issue: unknown, P. 167654 - 167654
Published: Jan. 1, 2025
Language: Английский
Citations
0RNA Modification in Metabolism
MedComm, Journal Year: 2025, Volume and Issue: 6(3)
Published: March 1, 2025
ABSTRACT Epigenetic regulation in disease development has been witnessed within this decade. RNA methylation is the predominant form of epigenetic regulation, and most prevalent modification N6‐methyladenosine (m 6 A). Recently, emerged as a potential target for treatment. posttranscriptional gene expression that involved both physiological pathological processes. Evidence suggests m A significantly affects metabolism, its abnormal changes have observed variety diseases. Metabolic diseases are series caused by metabolic processes body, common include diabetes mellitus, obesity, nonalcoholic fatty liver disease, etc.; although pathogenesis these differs from each other to current understanding, recent studies suggested pivotal role modulating diseases, A‐based drug on agenda. This paper reviewed understanding hoping provide systematic information those area.
Language: Английский
Citations
0Inflammation in MASLD Progression and Cancer
JHEP Reports, Journal Year: 2025, Volume and Issue: unknown, P. 101414 - 101414
Published: April 1, 2025
Language: Английский
Citations
0Potential therapeutic strategies for MASH: from preclinical to clinical development
Life Metabolism, Journal Year: 2024, Volume and Issue: 3(5)
Published: July 6, 2024
Current treatment paradigms for metabolic dysfunction-associated steatohepatitis (MASH) are based primarily on dietary restrictions and the use of existing drugs, including anti-diabetic anti-obesity medications. Given limited number approved drugs specifically MASH, recent efforts have focused promising strategies that target hepatic lipid metabolism, inflammation, fibrosis, or a combination these processes. In this review, we examined pathophysiology underlying development MASH in relation to advances effective therapy. Particularly, analyzed effects lipogenesis inhibitors, nuclear receptor agonists, glucagon-like peptide-1 (GLP-1) (GLP-1R) fibroblast growth factor mimetics, combinatorial therapeutic approaches. We summarize targets along with their preclinical clinical candidates ultimate goal optimizing prospects MASH.
Language: Английский
Citations
3Targeting fibroblast growth factor (FGF)-21: a promising strategy for metabolic dysfunction-associated steatotic liver disease treatment
Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16
Published: April 22, 2025
Metabolic dysfunction-associated steatitic liver disease (MASLD) is the predominant chronic disease, with its incidence increasing year by year. It has emerged as most rapidly contributor to liver-related mortality worldwide and becoming a principal cause of end-stage disorders, primarily cancer transplantation, hence putting substantial economic burden on public health. The approval Resmetirom signifies significant advancement in treatment metabolic steatohepatitis (MASH); nonetheless, heterogeneity MASLD renders it challenging for single medication address requirements all patients. Consequently, essential formulate varied therapeutic approaches distinct pathogenic causes phases disease. Fibroblast growth factor 21 (FGF21), member fibroblast family, plays positive protective role MASLD. attenuates hepatic steatosis lipotoxicity, ameliorates insulin resistance (IR), reduces oxidative stress, endoplasmic reticulum (ER) inflammation, well possesses anti-fibrotic effects. As result, FGF21 potential treat In this review, we will possible mechanisms therapy facilitate development clinical therapies targeting
Language: Английский
Citations
0Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Medicina, Journal Year: 2023, Volume and Issue: 59(10), P. 1789 - 1789
Published: Oct. 8, 2023
Metabolic-associated Fatty Liver Disease is one of the outstanding challenges in gastroenterology. The increasing incidence disease undoubtedly connected with ongoing obesity pandemic. lack specific symptoms early phases and grave complications require an active approach to prompt diagnosis treatment. Therapeutic lifestyle changes should be introduced a great majority patients; but, many cases, adherence not satisfactory. There need for effective pharmacological therapy Metabolic-Associated Disease, especially before onset steatohepatitis. Currently, there are no recommendations on selection drugs treat liver steatosis prevent patients from progression toward more advanced stages (steatohepatitis, cirrhosis, cancer). Therefore, this Review, we provide data clinical efficacy therapeutic interventions that might improve course Disease. These include used treatment hyperlipidemias, as well affecting gut microbiota endocrine system, other experimental approaches, including functional foods. Finally, advice concomitant
Language: Английский
Citations
9